Alzheimer's disease, dementia, mild cognitive impairment and the menopause: A 'window of opportunity'?

Women's Health

Volumn 9, Issue 3, 2013, Pages 279-290

  Davey, Dennis A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Alzheimer's disease; dementia; menopause; menopause hormonal therapy; MHT; mild cognitive impairment

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN D;

AGE DISTRIBUTION; ALZHEIMER DISEASE; COGNITION; DEMENTIA; DEPRESSION; DIET; DISEASE ASSOCIATION; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; MENOPAUSE; MILD COGNITIVE IMPAIRMENT; OVARIECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SLEEP DEPRIVATION;

HUMANS; IMMUNIZATION PROGRAMS; POPULATION SURVEILLANCE;

EID: 84877269373     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.22     Document Type: Review

References (102)

1. Barron AM, Pike CJ. Sex hormones, aging and Alzheimer's disease. Fron. Biosci. 4, 976-997 (2012).
2. Singh-Manoux A, Kivimaki M, Glymour MM et al. Timing of onset of cognitive decline; results from Whitehall II prospective cohort study. BMJ 344, d7622 (2011).
3. Tierney MC, Yao C, Kiss A, McDowell I. Neuropsychological tests accurately predict incident Alzheimer's disease after 5 and 10 years. Neurology 64, 853-859 (2005).
4. Blacker D, Lee H, Muzikansky A et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch. Neurol. 64, 862-871 (2007).
5. Maki PM, Sunderman E. Hormone therapy and cognitive function. Hum. Reprod. Update 15, 667-681 (2009).
6. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog. Neurobiol. 97, 38-51 (2012).
7. Alzheimer's Association. 2010 Alzheimer disease facts and figures. Alzheimers Dement. 6, 158-194 (2010).
8. Yaffe K, Middleton LE, Lui Y et al. Mild cognitive impairment, dementia and their subtypes in oldest old women. Arch. Neurol. 68, 631-636 (2011).
9. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960-969 (2011).
10. Sperling RA, Aiseb PS, Backett DA et al. Towards defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association work groups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292 (2011).
11. Lazarczyk MJ, Hof PR, Boura C, Giannakopoulos P. Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med. 10, 127(2012).
12. McMillan CT, Avants B. Irwin DJ et al. Can MRI screen for CSF biomarkers in neurodegenerative disease. Neurology 80, 132-138 (2013).
13. Fleisher AS, Chen K, Quiroz YT et al. Florbetapir PET binding of amyloid-b deposition in the presenilin 1 E289A autosomal dominant Alzheimer's kindred; a cross-sectional study. Lancet Neurol. 11, 1057-1065 (2012).
14. Reiman EM, Quiroz YT, Fleisher AS et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the prensenlin 1 E2804 kindred: a case-control study. Lancet Neurol. 11, 1048-1056 (2012).
15. Hall S, Ohrfelt A, Constantinescu R et al. Accuracy of a panel of 5 cerebrospinal fluid markers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch. Neurol. 69(11), 1445-1452 (2012).
16. Shaffer JL, Petrella JR, Sheldon FC et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging and PET biomarkers. Radiology 266(2), 583-591 (2013).
17. Serrano-Pozon A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Biol. 1(1), a006189 (2011).
18. Brayne C, Richardson K, Matthews FE et al. Neuropathological correlates of dementia in over-80-year old brain donors from the populations-based Cambridge city over-75s cohort (CC75C) STUDY. J. Alzheimers Dis. 18, 645-658 (2009).
19. Tabaton M, Zhu Z, Perry G, Smith MA, Gilberto L. Signaling effect of amyloid-b42 on the processing of AbPP. Exp. Neurol. 221, 18-25 (2010).
20. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ, Barr RK. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 1697(1-2), 89-101 (2004).
21. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid b protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 22, 4833-4841 (2002).
22. Baruch-Suchodolsky R, Fischer B. Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 48, 4354-4370 (2009).
23. Yao ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 16, 1677-1699 (2002).
24. Igbavboa U, Sun GY, Weisman GA, He Y, Wood WG. Amyloid beta protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience 162, 328-338 (2009).
25. Soscia SJ, Kirby JE, Wasjicosky et al. The Alzheimer's disease-associated amyloid b-protein is an antimicrobial peptide. PloS ONE 5, e9505 (2010).
26. Shankar GM, Li S, Mehta TH et al. Amyloid beta-protein dimers isolated directly from Alzheimer brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
27. Prelli F, Castano E, Glenner GG, Fragione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 51, 648-651 (1988).
28. Handoko M, Grant M, Kuskowski M et al. Correlation of specific amyloid-beta oligomers with Tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. doi:10.1001/jamaneurol.2013.48. (2013) (Epub ahead of print).
29. Ghiso J, Frangione B. Amylodosis and Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1539-1551 (2002).
30. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 32, 177-180 (2001).
31. Alzheimer's Association. 2008 Alzheimer's disease facts and figures. Alzheimers Dement. 4, 110-133 (2008).
32. Jack CR, Albert MS, Knopman DS et al. Introduction to revised criteria for the diagnosis of Alzheimer's Disease: National Institute on Aging and the Alzheimer's Association workgroups. Alzheimers Dement. 7, 257-282 (2011).
33. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269 (2011).
34. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's. Alzheimers Dement. 7, 270-279 (2011).
35. Budson AE, Solomon PR. New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. Pract. Neurol. 12, 88-96 (2012).
36. Seshadri M, Mazi-Kotawi N. A copyright-free alternative to the mini-mental state examination is needed. BMJ 345, e8589 (2012).
37. Cordell CB, Borson S, Boustani M et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 9(2), 141-150 (2013).
38. Plassman BL, Langa KM, Fisher GG et al. Prevalence of dementia in the United States: the Aging, Demographics, and Memory Study. Neuroepidemiology 29(1-2), 125-132 (2007).
39. Andersen K, Launer LJ, Dewey ME et al. Gender differences in the incidence of AD and vascular dementia: the EURODERM studies. EURODERM Incidence Research Group. Neurology 53, 1992-1997 (1999).
40. Spaminto MV. Sex differences in Alzheimer's disease development. Medscape News, 27 November (2012).
41. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum. Reprod. Update 13, 559-565 (2007).
42. Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroids. Front. Neuroendocrinol. 30, 239-258 (2009).
43. Kaya E, Sahin FK, Koken G, Kose M, Cevrioglu AS. Acute effect of intranasal estrogen on cerebral and cerebral perfusion in postmenopausal women. Maturitas 59, 72-82 (2008).
44. Resnick SM, Maki PM, Gloski S, Kraut MA, Zoderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm. Behav. 34, 171-182 (1998).
45. Henderson VW. Aging, estrogens and episodic memory in women. Cogn. Behav. Neurol. 22, 205-214 (2009).
46. Henderson VW, Popat RA. Effects of endogenous and exogenous estrogen exposures in midlife and late-life women on episodic memory and executive functions. Neuroscience 191, 129-138 (2011).
47. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet. Gynecol. Clin. North Am. 38, 519-535 (2011).
48. Weber MT, Rubin LH, Maki PM. Cognition in perimenopause: the effect of transition stage. Menopause doi:10.1097/gme.0b013e31827655e5 (2013) (Epub ahead of print).
49. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA 289, 2651-2662 (2003).
50. Shumaker SA. Legault C, Keller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
51. Resnick SM, Maki PM, Rapp SR et al. Effects of combination estrogen plus progestin hormone treatment on cognition. J. Clin. Endocrinol. Metab. 91, 1802-1810 (2006).
52. Resnick SM, Espeland MA, An Y et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J. Clin. Endocrinol. Metab. 94, 4152-4161 (2009).
53. Lethaby A, Hogervorst E, Richads M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst. Rev. 1, CD003122 (2008).
54. Hogervorst E, Bandelow S. Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. Maturitas 66, 56-71 (2010).
55. Le Blanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285, 1489-1499 (2011).
56. Rocca WA, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69, 1074-1083 (2007).
57. Bove R. Early surgical menopause linked to early cognitive decline. American Academy of Neurology 65th Annual Meeting Abstract 2946 report. Medscape News, 15 January (2013).
58. Sherwin BB, Grigorova M. Differential effects and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil. Steril. 96, 399-403 (2011).
59. Jodhka PK, Kaur P, Unerwoos W, Lydon JP, Singh M. The differences in neuroprotective efficacy of progesterone and metroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression. Endocrinology 150, 3162-3168 (2009).
60. Singh M, Su C. Progesterone and neuroprotection. Horm. Behav. 63, 284-290 (2013).
61. Wroolie TE, Kenna HA, Williams KE et al. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17b-estradiol versus conjugated equine estrogens. Am. J. Geriatr. Psychiatry 19, 793-802 (2011).
62. Dunkin J, Rasgon N, Wagner-Steh K, David S, Altshuler L, Rapkin A. Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postemenopausal women. Psychoneuroendocrinology 30, 284-296 (2005).
63. Yaffe K, Vittinghoff E, Ensrud KE et al. Effects of untra-low-does transdermal estradiol on cognition and health-realted quality of life. Arch. Neurol. 63, 945-950 (2006).
64. Pefanco MA, Kenny AM, Kaplan RF et al. The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. J. Am. Geriatr. Soc. 55, 426-431 (2007).
65. Joffe H, Hall JE, Gruber S et al. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomised imaging in perimenopausal and recently postmenopausal women. Menopause 13, 411-422 (2006).
66. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone therapy and the risk of stroke: a nested case-control study. BMJ 340, c2519 (2010).
67. Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronised progesterone. Climacteric 15(Suppl. 1), 11-17 (2012).
68. Maki PM. Minireview: effects of different HT formulations on cognition. Endocrinology 153, 3564-3570 (2012).
69. Zandi PP, Carlson MC, Plassman BL et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women: the Cache County Study. JAMA 288, 2123-2129 (2002).
70. Shao H, Breitner JC, Whitmer RA et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 79, 1846-1852 (2012).
71. Henderson VW, Benke KS, Green RC, Cupples LA, Farer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76, 103-105 (2005).
72. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical theory revisited. Ann. Neurol. 69, 163-169 (2011).
73. Craig MC, Murphy DG. Estrogen therapy and Alzheimers dementia. Ann. NY Acad. Sci. 1205, 245-253 (2010).
74. Davey DA. Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause. Womens Health (Lond. Engl.) 8, 169-189 (2012).
75. Henderson VW, Rocca W. Estrogens and Alzheimer's disease risk: is there a 'window of opportunity'. Neurology 79, 1840-1841 (2012).
76. Miller VM, Black DM, Brinton et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronor Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Trans. Res. 2, 1228-1239 (2009).
77. Daffner KR. Promoting successful cognitive aging: a comprehensive review. J. Alzheimers Dis. 19, 1101-1122 (2010).
78. Defina LF, Willis BL, Radford NB et al. The association between midlife cardiorespiratory fitness levels and later life dementia: a cohort study. Ann. Intern. Med. 158, 162-168 (2013).
79. Roberts RO, Geda YE, Cerhan JR et al. Vegetables, unsaturated fats, moderate alcohol intake and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 29, 413-423 (2010).
80. Geda YE, Ragossnig M, Roberts RO et al. Caloric intake, aging, and mild cognitive impairment: a population-based study. J. Alzheimers Dis. 34(2), 501-507 (2013).
81. Devore EE, Kang JH, Bretler MM, Grodstein F. Dietary intake of berries and flavonoids in relation to cognitive decline. Ann. Neurol. 72, 135-143 (2012).
82. Balion C, Griffith LE, Strifler L et al. Vitamin D, cognition, and dementia: a systematic review and analysis. Neurology 79, 1397-1405 (2012).
83. Anweiler C, Llewellyn CJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 33(3), 659-674 (2012).
84. Killgore WD. Effects of sleep deprivation on cognition. Prog. Brain Res. 185, 105-129 (2010).
85. Devore E. Sleep quality now may affect cognition later. Medscape News, 17 July (2012).
86. Ju YE, McLeland S, Toedebusch CD et al. Sleep Quality and Preclinical Alzheimer Disease. JAMA Neurol. doi: 10.1001/jamaneurol.2013.2334 (2013) (Epub ahead of print).
87. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, Whitmen RA. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer's disease and vascular dementia. Arch. Gen. Psychiatry 69, 493-498 (2012).
88. Spira AP, Rebok GW, Stone KL, Kramer JH, Yaffe K. Depressive symptoms in oldest-old women: risk of mild cognitive impairment and dementia. Am. J. Geriatr. Psychiatry 20, 1006-1015 (2012).
89. Reijnders J, van Heugten C, van Boxtel M. Cognitive interventions in healthy adults and people with mild cognitive impairment: a systematic review. Aging Res. Rev. 12, 263-275 (2012).
90. Park DC, Gutchess AH. Cognitive aging and everyday life. In: Cognitive Aging: A Primer. Park DC, Schwartz N (Eds). George H Buchanan, NJ, USA, 217-232 (2000).
91. Westerman SJ, Davies DR. Acquisition of new technology: the influence of age. Occup. Med. (Lond.) 50, 478-482 (2000).
92. Llandau SM, Marks SM, Mormino EC et al. Association of lifetime cognitive engagement and low b-amyloid deposition. Arch. Neurol. 69(5), 623-629 (2012).
93. White L. Beta-blockers linked to fewer Alzheimer's besions: Honolulu-Asia study. American Academy of Neurology's 65th meeting abstract 2171 report. Medscape News, 7 January (2013).
94. Hajjar I, Brown L, Mack WJ, Chui H. Impact of angiotensin blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch. Neurol. 69(12), 1632-1638 (2012).
95. Kern S, Skoog I, Ostling S, Kern J, Borjesson- Hanson A. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. BMJ Open 2, e001288 (2012).
96. Apostolakis S, Marin F, Lip GY. Antiplatelet therapy in stroke prevention. Adv. Cardiol. 47, 141-154 (2012).
97. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. Drug Targets 9, 132-139 (2010).
98. Forman MS. BACE inhibitor dramatically reduces amyloid-beta. Clinical Trials on Alzheimer's Disease (CTAD0 2012 conference Abstract OC) report. Medscape News, 12 November (2012).
99. Jinwal UK, Miyata Y, Koren J 3rd et al. Chemical manipulation of hsp70ATPase activity regulates tau stability. J. Neurosci. 29, 12079-12088 (2009).
100. Mathers C, Leonardi. Global burden of dementia in the year 2000: summary of methods and data sources. www.who.int/healthinfo/statistics/bod- dementia.pdf
101. ELITE: Early Versus Late Intervention Trial With Estradiol. http://clinicaltrials.gov/ct2/show/NCT00114517
102. KEEPS Cognitive and Affective Study. http://clinicaltrials.gov/ct2/show/ NCT00623311